Group 1 - The Hang Seng Index rose by 1.88%, gaining 470 points to close at 25,439 points, while the Hang Seng Tech Index increased by 2.35% [1] - The Hang Seng Biotechnology Index surged by 3.77%, driven by a collective rise in pharmaceutical stocks following the debut of the "dual directory" drug application, supporting a multi-layered and innovative strategic transformation [1] - Notable stock performances included Zhonghui Biotech-B (02627) up 24%, Jiuyuan Gene (02566) up 8.99%, and Innovent Biologics (01801) up 7.27% [1] Group 2 - Daqi Pharmaceutical-B (06996) saw a rise of over 15% as Claudin 18.2 ADC was proposed for breakthrough therapy designation [2] - Tencent-related companies reported generally better-than-expected earnings, with Tencent Music-SW (01698) up 15% and Reading Group (00772) also up over 15% [2] - Chongqing Machinery and Electric (02722) increased by 8.9%, anticipating a mid-term profit growth of approximately 50% due to rapid growth in AIDC power generation demand [2] Group 3 - Qiu Tai Technology (01478) rose over 8%, with a year-on-year profit increase of 167% in the first half, leading to target price upgrades from multiple institutions [3] Group 4 - Hongteng Precision (06088) increased by over 9% post-earnings, with a cumulative rise of over 60% in the month, reporting an 11% revenue growth but a 3% decline in net profit [4] - Minmetals Resources (01208) rose over 9% after reporting a 15-fold increase in net profit for the first half, while lowering cost guidance for its mining operations [5] Group 5 - 361 Degrees (01361) fell over 10% post-earnings, with institutions stating that the first half performance met expectations, but net profit growth was slightly lower than revenue growth [6]
港股午评 恒生指数早盘涨1.88% 恒生生物科技指数大涨3.77%
Jin Rong Jie·2025-08-13 05:00